Zhejiang Tianyu Pharmaceutical (300702.SZ) plans to invest 70 million yuan to participate in the establishment of the Defang Hongjing Equity Investment Fund.

Zhejiang Tianyu Pharmaceutical (300702.SZ) announced that the company has signed a Partnership Agreement with Shanghai Dehong Private Equity Fund Management Center (Limited Partnership), Linhai Jingyue Financial Investment Group Co., Ltd., and Linhai Hanhai Investment Co., Ltd. in Linhai City, Taizhou City, Zhejiang Province, to jointly invest in the establishment of Zhejiang Defang Hongjing Equity Investment Partnership (Limited Partnership). The total committed capital of the fund is 140 million yuan, of which the company, as a limited partner, will contribute 70 million yuan from its own funds, accounting for 49.96% of the total investment. It is reported that the fund intends to make direct equity investments in strategic emerging industries such as biopharmaceuticals and high-end equipment manufacturing, as well as in other industry sectors approved by the partner meetings. The company's investment aims to leverage the management experience and resource advantages of professional investment institutions to strategically position itself around the company's main business, further expand the industrial synergies in the biopharmaceutical field, and enhance the companys competitiveness.